Regeneron Pharmaceuticals, Inc. is an Americanbiotechnologycompany headquartered inWestchester County, New York. The company was founded in 1988.[2] Originally focused onneurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of bothcytokine andtyrosine kinase receptors, which gave rise to their first product, which is aVEGF-trap.
Regeneron has developedaflibercept, aVEGF inhibitor, andrilonacept, aninterleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.[citation needed]
On March 26, 2012, Bloomberg announced thatSanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than its competitors. The new drug would target thePCSK9 gene.[4]
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[5] with $640 million upfront, $750 million for proof-of-concept data, and $650 million from the development ofREGN2810.[6] REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best publicly listed company of the 2010s, with a total return of 1,457%.[7] Regeneron Pharmaceuticals was home to the two highest-paid pharmaceutical executives as of 2020.[8]
In October 2017, Regeneron made a deal with theBiomedical Advanced Research and Development Authority (BARDA) that the U.S. government would fund 80% of the costs for Regeneron to develop and manufacture antibody-based medications, which subsequently, in 2020, included theirCOVID-19 treatments, and Regeneron would retain the right to set prices and control production.[9] This deal was criticized inThe New York Times.[8] Such deals are not unusual for routine drug development in the American pharmaceutical market.
In May 2020, Regeneron announced it would repurchase approx. 19.2 million of its shares for around $5 billion, held directly by Sanofi. Prior to the transaction, Sanofi held 23.2 million Regeneron shares.[11][12]
In April 2022, the business announced it would acquireCheckmate Pharmaceuticals for around $250 million, enhancing its number of immuno-oncology drugs.[13]
In August 2023, Regeneron announced it would acquire Decibel Therapeutics.[14]
In December 2023, Regeneron acquired anAvon Products property inSuffern, New York to be used for cold storage, research and development laboratories[15]
In May 2025, the company was awarded $135.6 million in compensatory damages and $271.2 million in punitive damages in theUnited States District Court for the District of Delaware in a victorious antitrust case filed againstAmgen. Regeneron alleged Amgen employed anticompetitive practices to excludePraluent from the market and elevate Amgen's rivalRepatha.[17]
In July 2020, underOperation Warp Speed, Regeneron was awarded a $450 million government contract to manufacture and supply its experimental treatmentREGN-COV2, an artificial "antibody cocktail" which was then undergoing clinical trials for its potential both to treat people withCOVID-19 and to preventSARS-CoV-2 coronavirus infection.[19][20][21] The $450 million came from theBiomedical Advanced Research and Development Authority (BARDA), the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, andArmy Contracting Command. Regeneron expected to produce 70,000–300,000 treatment doses or 420,000–1,300,000 prevention doses. "By funding this manufacturing effort, the federal government will own the doses expected to result from the demonstration project," the government said in its July 7 news release.[22] Regeneron similarly said in its own news release that same day that "the government has committed to making doses from these lots available to the American people at no cost and would be responsible for their distribution," noting that this depended on the government grantingemergency use authorization or product approval.[23] California based laboratory, FOMAT, is part of the clinical investigation through their doctors Augusto and Nicholas Focil.[24]
In October 2020 when U.S. PresidentDonald Trump was infected withCOVID-19 and taken toWalter Reed National Military Medical Center inBethesda, Maryland, he was administeredREGN-COV2.[25] His doctors obtained it from Regeneron via acompassionate use request (as clinical trials had not yet been completed and the drug had not yet been approved by the USFood and Drug Administration (FDA)).[26] On October 7, Trump posted a five-minute video to Twitter reasserting that this drug should be "free."[27] That same day, Regeneron filed with the FDA for emergency use authorization. In the filing, it specified that it currently had 50,000 doses and that it expected to reach a total of 300,000 doses "within the next few months."[28] The FDA granted approval for emergency use authorization in November 2020.[29]
Eylea (aflibercept injection) was approved by the U.S. Food and Drug Administration (FDA) in November 2011[2][30] to treat a common cause of blindness in the elderly. Eylea is reported to cost $11,000 per year for each eye treated.[3]
Dupixent (dupilumab injection) is for the treatment of adolescent and adult patients'atopic dermatitis. It was approved by the FDA in March 2017[34] and is reported to cost $37,000 per year.[3]
Kevzara (sarilumab injection) is aninterleukin-6 (IL-6) receptor antagonist for treatment of adults withrheumatoid arthritis approved by the FDA in May 2017.[35] Trials commenced in March 2020 to evaluate the effectiveness of Kevzara in the treatment of COVID-19.[36][37]
Libtayo (cemiplimab injection) is a monoclonal antibody targeting the PD-1 pathway as a checkpoint inhibitor, for the treatment of people with metastatic cutaneoussquamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Libtayo was approved by the FDA in September 2018.[38]
Veopoz (pozelimab-bbfg) is a fully human monoclonal antibody targetingcomplement factor C5, a protein involved incomplement system activation. In August 2023, it was approved by the FDA for children and adults withCHAPLE disease orCD55-deficient protein-losing enteropathy.[40]
Trap Fusion Proteins: Regeneron's novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.[citation needed]
Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.[41]: 255–258
The founders Leonard Schleifer andGeorge Yancopoulos are reported to hold $1.3 billion and $900 million in company stock, respectively. Both are fromQueens, New York.[3] Schleifer was formerly a professor of medicine atWeill Cornell Medical School. Yancopoulos was a post-doctoral fellow, and MD/PhD student atColumbia University. Yancopoulos was involved in each drug's development.[3]
.jpg)
US$14.20 billion (2024)
US$3.991 billion (2024)
This article incorporates text from this source, which is in thepublic domain.